Serial 88171017
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 20 Feb 2026)
What this means for you
Registered since 26 Nov 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88171017
- Registration number
- 5922425
- Mark type
- Design / logo
- Filed
- 26 Oct 2018
- Published for opposition
- 05 Mar 2019
- Registered
- 26 Nov 2019
- Attorney of record
- Sonali S. Srivastava
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations and substances for the treatment of [ viral, metabolic, endocrine, ] musculoskeletal, [ cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ] ophthalmic, [ respiratory, neurological, ] gastrointestinal, [ hormonal , ] dermatological, [ psychiatric ] and immune system related diseases and disorders
Owner
- AbbVie Biotechnology Ltd, Pembroke, BM
- AbbVie Biotechnology Ltd, Hamilton, BM
- AbbVie Biotechnology Ltd, Hamilton, BM
Prosecution history
- 20 Feb 2026 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 20 Feb 2026 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 20 Feb 2026 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 17 Nov 2025 — TEAS SECTION 8 & 15 RECEIVED
- 26 Nov 2024 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 26 Nov 2019 — REGISTERED-PRINCIPAL REGISTER
- 22 Oct 2019 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 21 Oct 2019 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 21 Sept 2019 — STATEMENT OF USE PROCESSING COMPLETE
- 29 Aug 2019 — USE AMENDMENT FILED
- 21 Sept 2019 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 29 Aug 2019 — TEAS STATEMENT OF USE RECEIVED
- 30 Apr 2019 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 05 Mar 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 05 Mar 2019 — PUBLISHED FOR OPPOSITION